Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike

Rhea-AI Filing Summary

Cullinan Therapeutics director Mary Thistle received a stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and was granted at no cost to her.

The award vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, as long as she continues serving as a director on that date. Following this grant, she holds options for 25,319 underlying shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Thistle Mary

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,319	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 25,319 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 25,319 shares Exercise price: $13.55 per share Shares underlying option: 25,319 shares +2 more

5 metrics

Option grant size 25,319 shares Stock Option (Right to Buy) granted to director Mary Thistle

Exercise price $13.55 per share Conversion or exercise price of the stock option

Shares underlying option 25,319 shares Common Stock underlying the derivative security

Post-grant option holdings 25,319 derivative shares Total shares following transaction for this option award

Vesting date trigger June 16, 2027 Full vesting or earlier on date of next annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, vest in full, annual meeting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 13.5500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"which shall vest in full on the earlier of (i) June 16, 2027"

annual meeting financial

"or (ii) the date of the Issuer's next annual meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

continued service as a director financial

"subject to the Reporting Person's continued service as a director"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thistle Mary

(Last) (First) (Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.55	06/16/2026		A		25,319		(1)	06/16/2026	Common Stock	25,319	$0	25,319	D

Explanation of Responses:

1. The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Cullinan Therapeutics (CGEM) disclose about Mary Thistle’s latest Form 4?

Cullinan Therapeutics reported that director Mary Thistle received a stock option grant for 25,319 shares at a $13.55 exercise price. The options were granted at no cost and represent equity-based compensation tied to her board service.

How many stock options did Mary Thistle receive from Cullinan Therapeutics (CGEM)?

Mary Thistle was granted stock options covering 25,319 shares of Cullinan Therapeutics common stock. These options provide the right to buy that number of shares if exercised in the future in accordance with the grant’s terms.

What is the exercise price of Mary Thistle’s Cullinan Therapeutics (CGEM) option grant?

The grant to Mary Thistle carries an exercise price of $13.55 per share. This means she can purchase Cullinan Therapeutics common stock at $13.55 for each of the 25,319 shares underlying the option, once the award is fully vested and exercisable.

When do Mary Thistle’s Cullinan Therapeutics (CGEM) options vest?

The options granted to Mary Thistle vest in full on the earlier of June 16, 2027 or the date of Cullinan Therapeutics’ next annual meeting. Vesting is contingent on her continued service as a director through the applicable vesting date.

Is Mary Thistle’s Cullinan Therapeutics (CGEM) option grant tied to her director role?

Yes. The filing states the 25,319-share option vests only if Mary Thistle continues serving as a director through the vesting date. This links the equity award directly to her ongoing board service at Cullinan Therapeutics.